DelveInsight’s “HER2+ Gastric Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the HER2+ Gastric Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The HER2+ Gastric Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
HER2+ Gastric Cancer: An Overview
Gastric (stomach) cancer occurs when cancer cells form in the lining of the stomach. Risk factors include smoking, infection with H. pylori bacteria, and certain inherited conditions. Gastric cancer consists of two pathological variants, intestinal and diffuse.
Currently, patients with advanced HER2-positive gastric cancer have limited options in the second-line setting and beyond and include options such as irinotecan or paclitaxel/ramucirumab. But, recent resultsthe from DESTINY-Gastric01 trial, have shown the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu) elicited a higher objective response rate (ORR) compared with chemotherapy in patients with advanced, HER2-positive gastric or GEJ adenocarcinoma who had progressed following trastuzumab (Herceptin)-containing treatment.
HER2+ Gastric Cancer Market Key Facts
-
The stomach is the most commonly involved site (60%-75%) in the gastrointestinal tract followed by the small bowel, ileocecal region, and rectum. Several different types of cancer can occur in the stomach. The most common type is called adenocarcinoma. Approximately 90% of gastric cancers are adenocarcinoma, although it is uncommon in the United States. It occurs most often in men over age 40.
-
Gastric carcinoma (GC) is the fourth most common malignancy worldwide (989,600 new cases per year in 2008) and remains the second cause of death (738,000 deaths annually) of all malignancies worldwide.
-
It is observed that males have a higher prevalence of HER2+ Gastric Cancer as compared to females.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted HER2+ Gastric Cancer market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the HER2+ Gastric Cancer market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
HER2+ Gastric Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
HER2+ Gastric Cancer Epidemiology Segmentation
-
Total Treatable Pool of HER2+ Gastric Cancer
-
Diagnosed Incidence Pool of HER2 positive Gastric Cancer
-
Stage-specific Pool of HER2+ Gastric Cancer
-
Gender-specific Pool of HER2+ Gastric Cancer
HER2+ Gastric Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the HER2+ Gastric Cancer market or expected to get launched during the study period. The analysis covers HER2+ Gastric Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the HER2+ Gastric Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
HER2+ Gastric Cancer Therapeutics Analysis
As per DelveInsight, the dynamics of the HER2+ Gastric Cancer market are anticipated to evolve in the coming years due to the rise in healthcare spending worldwide, the launch of emerging therapies, and the extensive research and development (R&D) activities of pharmaceutical companies.
There are approx. 15+ key companies which are developing therapies for HER2 Positive Gastric Cancer. Currently, GeneQuantum Healthcare has its HER2 Positive Gastric Cancer drug candidates in the most advanced stage of clinical development.
Major Players in HER2 Positive Gastric Cancer Therapeutics Market include:
• Roche
• GeneQuantum Healthcare
• MacroGenics
• Pieris Pharmaceuticals, Inc.
• Bellicum Pharmaceuticals
• Acepodia Biotech Inc.
• Bristol-Myers Squibb
• Klus Pharma Inc.
• Carisma Therapeutics Inc
• Hanmi Pharmaceutical
• Jiangsu Alphamab Biopharmaceuticals Co., Ltd
• Shanghai Miracogen Inc.
• Imugene Limited
• BeiGene
• Shanghai PerHum Therapeutics Co., Ltd.
• ALX Oncology
• BOLT BIOTHERAPEUTICS
• Imugene
And many others
HER2+ Gastric Cancer Therapies covered in the report include:
• RC48
• Enhertu
• Zolbetuximab
• Herceptin
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. HER2+ Gastric Cancer Competitive Intelligence Analysis
4. HER2+ Gastric Cancer Market Overview at a Glance
5. HER2+ Gastric Cancer Disease Background and Overview
6. HER2+ Gastric Cancer Patient Journey
7. HER2+ Gastric Cancer Epidemiology and Patient Population
8. HER2+ Gastric Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. HER2+ Gastric Cancer Unmet Needs
10. Key Endpoints of HER2+ Gastric Cancer Treatment
11. HER2+ Gastric Cancer Marketed Products
12. HER2+ Gastric Cancer Emerging Therapies
13. HER2+ Gastric Cancer Seven Major Market Analysis
14. Attribute Analysis
15. HER2+ Gastric Cancer Market Outlook (7 major markets)
16. HER2+ Gastric Cancer Access and Reimbursement Overview
17. KOL Views on the HER2+ Gastric Cancer Market.
18. HER2+ Gastric Cancer Market Drivers
19. HER2+ Gastric Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/her2-positive-gastric-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/